Actavis hit with IP suit over prostate cancer drug
Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi (enzalutamide), a treatment for prostate cancer.
The suit, which was filed on Friday, December 2 in the US District Court for the District of Delaware, involves US patent numbers 7,709,517; 8,183,274; and 9,126,941.
The dispute arose after Actavis filed an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration seeking approval to market a generic version of Xtandi before the expiration of the patents involved.
Xtandi is sold and co-promoted by Astellas Pharma and Medivation in the US, where they have been granted an exclusive licence by the regents, which owns the patents.
The suing companies have asked the district court for a judgment that says claims of the three patents have been infringed by Actavis by submitting the ANDA.
They are further seeking a permanent injunction restraining Actavis from bringing a generic product of Xtandi to market, as well an award of costs.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk